Hormone therapy: Physiological complexity belies therapeutic simplicity

Science

Volumn 304, Issue 5675, 2004, Pages 1269-1273

  Turgeon, Judith L ^a   McDonnell, Donald P ^c   Martin, Kathryn A ^d   Wise, Phyllis M ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG THERAPY; HEALTH RISKS;

HORMONE THERAPY; OVARIAN HORMONES;

HORMONES;

ESTROGEN; GESTAGEN; PROGESTERONE; STEROID HORMONE;

HORMONE; WOMENS HEALTH;

CLINICAL PROTOCOL; DRUG DEVELOPMENT; DRUG MECHANISM; ESTROGEN THERAPY; HEALTH HAZARD; HORMONAL THERAPY; HORMONE ACTION; HUMAN; MOLECULAR BIOLOGY; NEUROPROTECTION; POSTMENOPAUSE; PRIORITY JOURNAL; REVIEW; TISSUE REACTION;

AGED; ANIMALS; CARDIOVASCULAR PHYSIOLOGY; CEREBROVASCULAR ACCIDENT; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMANS; LIPID METABOLISM; MEDROXYPROGESTERONE 17-ACETATE; MIDDLE AGED; NEUROPROTECTIVE AGENTS; PROGESTERONE; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SIGNAL TRANSDUCTION;

EID: 2542540731     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.1096725     Document Type: Review

References (51)

1. J. E. Manson, K. A. Martin, N. Engl. J. Med. 345, 34 (2001).
2. J. E. Rossouw et al., J. Am. Med Assoc. 288, 321 (2002).
3. G. L. Anderson et al., J. Am. Med. Assoc. 291, 1701 (2004).
4. www.nhlbi.nih.gov/whi/.
5. B. R. Bhavnani, J. Steroid Biochem. Mol. Biol. 85, 473 (2003).
6. X. Liu et al., Chem. Res. Toxicol. 15, 512 (2002).
7. I. F. Godsland, Fertil. Steril. 75, 898 (2001).
8. T. S. Mikkola, T. B. Clarkson, Cardiovasc. Res. 53, 605 (2002).
9. R. J. Chetkowski et al., J. Med. 314, 1615 (1986).
10. T. J. Key et al., J. Natl. Cancer Inst. 95, 1218 (2003).
11. M. W. Rajala, P. E. Scherer, Endocrinology 144, 3765 (2003).
12. A. M. Shearman et al., J. Am. Med. Assoc. 290, 2263 (2003).
13. D. M. Herrington et al., Circulation 105, 1879 (2002).
14. J. Gao, J. Mazella, M. Tang, L. Tseng, Mol. Endocrinol. 14, 1954 (2000).
15. M. Otsuki et al., Arterioscler. Thromb. Vasc. Biol. 21, 243 (2001).
16. C. M. Bamberger, T. Else, A. M. Bamberger, F. U. Beil, H. M. Schulte, J. Clin. Endocrinol. Metab. 84, 4055 (1999).
17. K. Miyagawa, J. Rosch, F. Stanczyk, K. Hermsmeyer, Nature Med. 3, 324 (1997).
18. A. P. Miller, Y. F. Chen, D. Xing, W. Feng, S. Oparil, Hypertension 42, 657 (2003).
19. J. Nilsen, R. D. Brinton, Proc. Natl. Acad. Sci. U.S.A. 100, 10506 (2003).
20. J. A. Gustafsson, Trends Pharmacol. Sci. 24, 479 (2003).
21. J. M. Hall, J. F. Couse, K. S. Korach, J. Biol. Chem. 276, 36869 (2001).
22. H. A. Harris et al., Endocrinology 144, 4241 (2003).
23. E. Vegeto et al., Proc. Natl. Acad. Sci. U.S.A. 100, 9614 (2003).
24. S. C. Manolagas, S. Kousteni, R. L. jilka, Recent Prog. Horm. Res. 57, 385 (2002).
25. R. M. Lösel et al., Physiol. Rev. 83, 965 (2003).
26. M. E. Mendelsohn, Am. J. Cardiol. 90, 3F (2002).
27. D. P. McDonnell, C. E. Connor, A. Wijayaratne, C. Y. Chang, J. D. Norris, Recent Prog. Horm. Res. 57, 295 (2002).
28. C. L. Smith, B. W. O'Malley, Endocr. Rev. 25, 45 (2004).
29. C. W. Gregory et al., J. Clin. Endocrinol. Metab. 87, 2960 (2002).
30. A. K. Shiau et al., Cell 95, 927 (1998).
31. J. M. Hall, D. P. McDonnell, K. S. Korach, Mol. Endocrinol. 16, 469 (2002).
32. C. W. Wong, C. McNally, E. Nickbarg, B. S. Komm, B. J. Cheskis, Proc. Natl. Acad. Sci. U.S.A. 99, 14783 (2002).
33. P. Webb, P. Nguyen, P. J. Kushner, J. Biol. Chem. 278, 6912 (2003).
34. C. K. Osborne et al., J. Natl. Cancer Inst. 95, 353 (2003).
35. X. Li, B. W. O'Malley, J. Biol. Chem. 278, 39261 (2003).
36. S. A. Leonhardt, V. Boonyaratanakornkit, D. P. Edwards, Steroids 68, 761 (2003).
37. P. H. Giangrande, D. P. McDonnell, Recent Prog. Horm. Res. 54, 291 (1999).
38. J. K. Richer et al., J. Biol. Chem. 277, 5209 (2002).
39. P. A. Mote, S. Bartow, N. Tran, C. L. Clarke, Breast Cancer Res. Treat. 72, 163 (2002).
40. J. Sun et al., Endocrinology 143, 941 (2002).
41. H. Z. Ke, G. L. Foley, H. A. Simmons, V. Shen, D. D. Thompson, Endocrinology 145, 1996 (2004).
42. F. Labrie et al., Endocrinology 144, 4700 (2003).
43. Y. Shang, M. Brown, Science 295, 2465 (2002).
44. L. Zhi et al., J. Med. Chem. 46, 4104 (2003).
45. K. M. Dhandapani, D. W. Brann, Biol. Reprod. 67, 1379 (2002).
46. L. D. McCullough, P. D. Hurn, Trends Endocrinol. Metab. 14, 228 (2003).
47. P. M. Wise, D. B. Dubal, M. E. Wilson, S. W. Rau, Y. Liu, Front. Neuroendocrinol. 22, 33 (2001).
48. S. H. Yang et al., Proc. Natl. Acad. Sci. U.S.A. 101, 4130 (2004).
49. W. Vongpatanasin et al., J. Am. Coll. Cardiol. 41, 1358 (2003).
50. E. Oger et al., Arterioscler. Thromb. Vasc. Biol. 23, 1671 (2003).
51. Space limitations prevent complete referencing of original studies and recent interesting work, clinical and basic. We thank N. Schwartz and D. Waring for insightful criticism and D.W. for creative contributions to figure design. Support was provided by NIH grants HD12137 and DK66606 (J.L.T.); DK48807 and DK50495 (D.P.M.); AG02224 and AG17164 (P.M.W.); and the Ellison Foundation (P.M.W.). D.P.M. owns equity in and is on the Scientific Advisory Board of Ligand Pharmaceuticals, which develops drugs for female health problems. He has also been a consultant for the Women's Health Institute, Wyeth Pharmaceuticals.